De Backer Marianne 4
4 · Vir Biotechnology, Inc. · Filed Feb 26, 2026
Research Summary
AI-generated summary of this filing
Vir Biotechnology (VIR) CEO Marianne De Backer Sells 14,762 Shares
What Happened Marianne De Backer, CEO of Vir Biotechnology (VIR), sold 14,762 shares on 2026-02-24 at $9.53 per share, generating proceeds of $140,720. The filing shows this was a sale (S) and, per the filer, an automatic transaction to satisfy tax withholding tied to vesting restricted stock units—not a discretionary trade.
Key Details
- Transaction date: 2026-02-24; Filing date: 2026-02-26 (timely).
- Price: $9.53 per share; Shares sold: 14,762; Gross proceeds: $140,720.
- Reason/footnote: Sale executed under a Rule 10b5-1 arrangement to cover tax withholding on RSU vesting (automatic/mandatory; not discretionary).
- Shares held in the name of the Ureel‑De Backer Family Trust; Marianne De Backer and her spouse are trustees (per footnote).
- Shares owned after the transaction: not specified in the filing.
Context This was a sale to satisfy tax obligations related to vested restricted stock units, a common and typically routine insider transaction; it should not be interpreted as a discretionary signal about company prospects. For retail investors, purchases by insiders tend to be more indicative of bullish sentiment than tax‑withholding sales like this one.
Insider Transaction Report
- Sale
Common Stock
[F1]2026-02-24$9.53/sh−14,762$140,720→ 1,020,704 total
- 53,118(indirect: See Footnote)
Common Stock
[F2]
Footnotes (2)
- [F1]Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person.
- [F2]The shares are held in the name of the Ureel-De Backer Family Trust, of which the Reporting Person and her spouse are Trustees.